Longer duration of B cell depletion is associated with better outcome

Rheumatology (United Kingdom)

Volumn 54, Issue 10, 2015, Pages 1876-1881

  Dias, Sofia Sapeta ^a,b,c   Rodriguez garcia, Veronica ^a,b,c   Nguyen, Hanh ^a,b,c   Pericleous, Charis ^a,b,c   Isenberg, David ^a,b,c  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B cells; DsDNA antibodies; Outcome; Remission; SLE

Indexed keywords

COMPLEMENT; DNA ANTIBODY; LA ANTIBODY; METHYLPREDNISOLONE; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SM ANTIBODY;

ALLERGIC REACTION; ALOPECIA; ARTHROPATHY; ARTICLE; B CELL DEPLETION THERAPY; B LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; ETHNICITY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; SJOEGREN SYNDROME; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

EID: 84943813069     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev036     Document Type: Article

References (19)

1. Adler M, Chambers S, Edwards C, Neild G, Isenberg D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology 2006;45:1144-7.
2. Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin Immunol 2013;146:90-103.
3. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46: 2673-7.
4. Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009;24: 3717-23.
5. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
6. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
7. Condon MB, Ashby D, Pepper RJ et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
8. Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 2012;51: 476-81.
9. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9.
10. Albert D, Dunham J, Khan S et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008;67:1724-31.
11. Reddy V, Croca S, Gerona D et al. Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology 2013;52:951-2.
12. Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90.
13. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-doublestranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013;65:2672-9.
14. Stohl W, Metyas S, Tan S-M et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48:3475-86.
15. Vital EM, Dass S, Buch MH et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011;63:3038-47.
16. Ng KP, Cambridge G, Leandro MJ et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62.
17. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447-58.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for theclassification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
19. Bosma A, Abdel-Gadir A, Isenberg DA, Jury EC, Mauri C. Lipid-antigen presentation by CD1d+ B cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012, 36-20:477-90.